Suppression of CEP55 reduces cell viability and induces apoptosis in human lung cancer

LIGANG LIU², QI MEI¹, JING ZHAO¹, YUHONG DAI¹ and QIANG FU¹

Departments of ¹Oncology and ²Cardiothoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China

Received April 6, 2016; Accepted May 12, 2016

DOI: 10.3892/or.2016.5059

Abstract. Centrosomal protein 55 (CEP55), identified as a centrosome-associated protein, has been reported to be involved in human malignancies. However, its biological function in human lung cancer remains largely unknown. In the present study, we firstly analyzed the expression of CEP55 in 20 pairs of lung cancer and matched non-tumor tissues using quantitative RT-PCR analysis and found that CEP55 mRNA was significantly increased in lung cancer tissues compared with that in matched tumor-adjacent tissues. Then we performed a loss-of-function assay using lung cancer cell lines A549 and 95D. Functionally, knockdown of CEP55 markedly inhibited cell viability and proliferation ability as determined by MTT and colony formation assays. Moreover, CEP55-silenced cells were obviously arrested in the G0/G1 phase and presented significant cell apoptosis as determined using flow cytometric analysis. Mechanistically, western blot analysis further revealed that knockdown of CEP55 decreased the expression of CDK4, p21 and Bcl-2, while it increased the expression of pro-apoptotic protein, Bad, caspase-3 and PARP in 95D cells. In conclusion, our data highlight the crucial role of CEP55 in promoting lung cancer cell proliferation in vitro and its inhibition may be a novel therapeutic strategy for lung cancer.

Introduction

Lung cancer, mostly caused by smoking and exposure to pollutants, is one of the leading causes of death worldwide (1). According to its histological types, lung cancer is classified into small cell lung cancer and non-small cell lung cancer (NSCLC). For many years, the existing therapeutic strategies for lung cancer have been several traditional therapies, including surgery, chemotherapy and radiotherapy. Despite the advances in these traditional therapies, the mortality rates remain high, with an overall 5-year survival of only 15% (2). Therefore, comprehensive understanding of the molecular mechanisms underlying lung cancer progression may contribute to the effectiveness of anticancer therapy and thereby, the overall survival of lung cancer.

Centrosomal protein 55 (CEP55), also named C10orf3 (3) and URCC6, is the latest member found in the centrosomal relative protein family, which upon observation was revealed to localize to the centrosome in interphase cells, midzone during anaphase, and the midbody during cytokinesis by tagging with GFP-C (4-6). Furthermore, CEP55 has been identified as a microtubule-bundling protein and plays an important role in cell mitosis through cooperation with CDK1, ERK2 and PLK1 (4). Accumulated evidence has shown that CEP55 overexpression occurs in a wide range of solid tumors, including human colon (3), bladder cancer (7) and hepatocellular carcinoma tumorigenesis (8). In addition, CEP55 has been demonstrated to regulate critical cell functions including cell growth, transformation and cytokinesis. Overexpression of CEP55 was found to enhance cell cycle transition by activation of p21, whereas knockdown of CEP55 was found to inhibit cell growth in gastric (9) and breast cancer (10). Moreover, CEP55 was found to be upregulated by VEGFA in lung cancer tissues and associated with metastasis (11). In spite of these functional observations, the role of CEP55 in lung cancer has remained largely unclear.

The present study aimed to further investigate the biological function of CEP55 in lung cancer. We found that CEP55 was overexpressed in lung cancer tissues and cell lines. Our in vitro studies demonstrated that CEP55 promoted cell viability and proliferation through cell cycle progression and inhibition of apoptosis. These findings suggest that CEP55 overexpression is associated with tumor growth and may serve as a potential new therapeutic target for lung cancer.

Materials and methods

Clinical tissue specimens. A total of 20 fresh tumor tissue samples with paired non-cancerous lung tissue samples were derived from lung cancer patients who had undergone surgery at our institution. None of these patients had received radiotherapy.
or chemotherapy prior to surgical treatment. Dissected samples were frozen immediately after surgery and stored at -80°C until use. All patients had signed written informed consents prior to the use of the clinical materials for this study.

**Cell lines and culture.** The human NSCLC cell lines H1299, A549, H128 and 95D were purchased from the Cell Bank of the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). These cells were cultured in RPMI-1640 (Hyclone and Biowest) supplemented with 10% fetal bovine serum (FBS) and incubated in a humidified atmosphere containing 5% CO₂. The medium was replaced every 2-3 days as indicated.

**CEP55 short hairpin RNA (shRNA) stable transfection.** Two CEP55 shRNA constructs, as well as a scrambled negative control (NC) shRNA were purchased from OriGene Technologies, Inc. (Rockville, MD, USA) and cloned into the pLKO.1-EGFP vector between AgeI and EcoRI restriction sites. Lentivirus particles were generated by co-transfecting recombinant and packing vectors into 293T cells via Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). A549 and 95D cells were then cultured in 6-well plates and transfected with CEP55 shRNA-expression lentiviruses (sh-1 or -2) according to the manufacturer's instructions. All transfected cell lines were further evaluated for knockdown efficiency of the target gene (CEP55) using quantitative real-time PCR (qRT-PCR) and western blot analysis.

**Quantitative RT-PCR.** Total RNA was isolated using the TRIzol reagent (Invitrogen). Complementary DNA (cDNA) was synthesized from 2 μg of total RNA using 200 U/ml SuperScript II Reverse Transcriptase (Invitrogen). Real-time PCR amplification reactions for CEP55 were carried out using the Bio-Rad Connect Real-Time PCR platform as previously reported (12). All reagents were purchased from Thermo Fisher Scientific (Waltham, MA, USA). The relative mRNA expression of CEP55 was normalized by using human GAPDH mRNA levels as an internal control. Data were analyzed using the 2⁻ΔΔCt method as previously described (13). Each experiment was performed in triplicate.

**Protein isolation and western blot analysis.** Total protein was isolated from cells using RIPA lysis buffer containing protease inhibitors (Sigma-Aldrich, St. Louis, MO, USA). The suspension was collected after centrifugation at 12,000 x g for 15 min at 4°C, followed by protein concentration determination using BCA assay. Equal amounts of proteins (20-40 μg) were blocked with TBST (Tris-buffered saline, 0.1% Tween-20) containing 5% non-fat dry milk for 1 h at room temperature, and probed with the corresponding primary antibodies overnight. Subsequently, the membrane was incubated with appropriated horseradish peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) for 2 h at room temperature. Immunoreactive bands were visualized using Super ECL detection reagent (Applygen Technologies, Inc., Beijing, China).

**Cell viability assay.** MTT assay was used to determine cell viability in the A549 and 95D cells. Briefly, the cells were seeded into 96-well plates in triplicates at a density of 2,000 cells/well and cultured for 24 h. Then 50 μl MTT was added into each well at 1, 2, 3, 4, and 5 days after transfection. After 4 h of incubation, 200 μl dimethyl sulfoxide (DMSO) was added into each well. The absorbance value was measured using a microplate reader at 595 nm. Each experiment was performed in triplicate.

**Colony formation assay.** To evaluate the effect of CEP55 on monolayer colony formation, stably transfected cells were seeded into 6-well plates at a density of 1,500 cells/well and allowed to grow for 7 days to form colonies. After being cultured for 7 days, the cells were fixed with methanol and stained with crystal violet. The number of colonies consisting of >50 cells/colony was counted under a microscope. Each experiment was performed in triplicate and repeated three times.

**Cell cycle and apoptosis analysis.** Cells were washed with cold PBS twice after a 48-h transfection and re-inoculated into 6-cm dishes at a density of 80,000 cells/dish. Then the cells were collected and stained with propidium iodide (PI). The number of cells in each cell cycle phase was analyzed using a flow cytometer (FACSCalibur; BD Biosciences). In addition, apoptosis was determined by dual staining with an Annexin V-APC and PI apoptosis detection kit (Nanjing KeyGen Biotech, Co., Ltd., Nanjing, China) according to the manufacturer's instructions.

**Statistical analysis.** All statistical analyses were performed by SPSS software version 10.0 (SPSS, Inc., Chicago, IL, USA) and expressed as the mean ± standard deviation (SD) of three independent experiments. Paired Student's t-test was used to compare differences between the groups. Statistically significant differences were accepted at p<0.05.

**Results**

**CEP55 is upregulated in lung cancer tissues and cell lines.** To investigate the expression of CEP55 in lung cancer, we performed quantitative RT-PCR to detect CEP55 mRNA expression in 20 fresh tumor tissue samples with paired non-cancerous lung tissues. As shown in Fig. 1A, the mRNA level of CEP55 was significantly elevated in the lung cancer tissues compared with that noted in the adjacent normal tissues (p<0.001). Next, we further determined CEP55 expression in four lung cancer cell lines by western blot analysis. The results indicated that the protein level of CEP55 was obviously increased in all four lung cancer cell lines, among which it was expressed at a higher level in the A459 and 95D cells (Fig. 1B). Thus, A459 and 95D cells were chosen for the following studies.

**The expression of CEP55 is significantly suppressed in lung cancer cells.** To study the potential function of CEP55, we designed two shRNA constructs to specifically silence CEP55 expression in the A549 and 95D cells using a lentiviral system. Subsequently, we determined the knockdown efficiency on
CEP55 mRNA and protein levels in the A549 and 95D cells. As shown in Fig. 2A and C, the CEP55 mRNA level was significantly decreased in the sh-CEP55-infected cells. Notably, we found that the second construct (sh-2) (p<0.001) showed better inhibiting efficiency than sh-1 (p<0.05, p<0.01) in both cell lines compared with the first constructs (sh-1). Similarly, sh-2 suppressed the CEP55 protein level more markedly than sh-1 in the A549 and 95D cells (Fig. 2B and D). Therefore, sh-2 was selected for further experiments.

CEP55 knockdown inhibits lung cancer cell viability and colony formation ability. To investigate the inhibitory effect of CEP55 on cell growth, we measured cell viability using an MTT assay and found that the cell viability was significantly lower after five consecutive days in the CEP55-knockdown (sh-2) cells compared with that noted in the non-target scramble control shRNA-transfected cells (sh-NC) in both the A549 and 95D cell lines (Fig. 3A, p<0.001). Furthermore, we determined the colony formation ability of the lung cancer cells after knockdown of CEP55. As shown in Fig. 3B, knockdown of CEP55 obviously reduced the size of the single colonies and the number of colonies formed in the A549 and 95D cells. The number of colonies in the sh-2 group was apparently smaller than that in the sh-NC group in both cell
These results further indicate that CEP55 acts as a potential tumor gene in lung cancer.

Cell cycle arrest and apoptosis is induced by knockdown of CEP55 in lung cancer cells. To explore the underlying mechanism of reduced cell viability by CEP55 inhibition, flow cytometry was used to analyze the cell cycle distribution in lung cancer cells. The results showed that the percentage of cells in the G1 phase (p<0.001) was greatly increased in the CEP55-knockdown cells compared to the control cells in both the A549 (Fig. 4A and C) and 95D cell lines (Fig. 4B and D). In addition, more cells were accumulated in the sub-G1 phase in the sh-2 infected 95D cells; much more than those in the sh-NC infected cells (Fig. 4E, p<0.001). Next, we evaluated cell apoptosis using Annexin V staining and flow cytometry. Our results showed that, the percentages of both early apoptotic (Annexin V+/PI-) and late apoptotic (Annexin V+/PI+) cells in the CEP55 sh-2-transfected cells were increased significantly compared with those in the control shRNA-transfected cells (Fig. 5A). Further analysis indicated that knockdown of CEP55 markedly increased the overall apoptotic cells in the A549 and 95D cell lines (Fig. 5B, p<0.001).

Molecular targets of CEP55 in lung cancer cells. To gain insight into the molecular mechanisms of CEP55 silencing on cell cycle and apoptotic regulation, several molecular...
targets associated with cell cycle and apoptotic regulation were assessed by western blot analysis in the 95D cells stably transfected with sh-2. As shown in Fig. 6, knockdown of CEP55 inhibited expression of CDK4 and Bcl-2 and enhanced expression of p21, cell cycle regulators. Moreover, Bad, caspase-3 and PARP with pro-apoptotic effects were significantly upregulated in the sh-2-transfected cells compared with that in the sh-NC-transfected cells. These results suggest that CEP55 acts as an oncogene by regulating...
the expression of important genes involved in the proliferation and apoptotic pathways.

Discussion

NSCLC, as a major type, accounts for >80% of all lung cancers. Molecular targeted therapy has been widely applied for the treatment of lung cancer with higher efficacy and lower toxicity compared with traditional chemotherapy. Therefore, it is of great importance to identify specific tumor genes and therapeutic targets to improve personalized cancer therapy. CEP55 has been reported to be overexpressed in various human cancer tissues like epithelial ovarian (14) and gastric (9) carcinomas. For these studies, we hypothesized that CEP55 was overexpressed in lung cancer tissues and cell lines. To confirm this hypothesis, we firstly determined the expression of CEP55 in tumor tissues from lung cancer patients and found that it was highly expressed in tumor tissues compared with normal lung tissues. Herein, previous study indicated that VEGFA upregulated the expression of the CEP55 protein, which subsequently resulted in the complex formation with PI3K (11). Therefore, these results suggest a potential oncogenic role of CEP55 in lung cancer, and motivated us to explore its functional significance in lung cancer.

In the present study, the in vitro studies demonstrated that CEP55 knockdown inhibited cell viability and proliferation through the induction of cell cycle arrest and apoptosis in the NSCLC cell lines A549 and 95D, indicating antitumor activity of CEP55 inhibition. Evidence points to the contribution of CEP55 in cell proliferation involved in gastric (9) and breast (10) cancers, as well as nasopharyngeal carcinomas (15). To the best of our knowledge, dysregulation of cell proliferation is the key characteristic of cancer cells, which is closely associated with cell cycle regulation (16,17). As one of the main checkpoints of the cell cycle, the G1/S transition plays a crucial role in the initiation and completion of DNA replication, which is strongly regulated by the CDK/cyclin complex activity (18,19). In addition CDKs, cyclin-dependent kinase inhibitors (CDKIs) also suppress the G1/S transition in cell cycle regulation (20). Our results showed that cells were arrested in the G1 phase in the CEP55 knocked-down cells. Consistently, further analysis revealed that knockdown of CEP55 downregulated the expression of CDK4 and upregulated the expression of CDKI p21. It has been widely accepted that centrosome-associated proteins play an essential role in cell cycle progression (21,22). Thus, we conclude that CEP55, as a member of the centrosome-associated protein family promotes cell cycle progression in cancer occurrence.

Additionally, we further found that knockdown of CEP55 induced cell apoptosis in the NSCLC cell lines A549 and 95D. Caspase cascade plays a central role in apoptosis, whose activation is regulated by various factors, among which the Bcl-2 family of proteins, as anti-apoptotic mitochondria proteins, are the principle regulators in the intrinsic mitochondrial apoptotic pathway (23). In addition, pro-apoptotic proteins, such as Bad and caspase-3 may be activated in cell apoptosis (24,25). As the specificity substrate of caspases, PARP plays an important role in DNA repair and can be cleaved by activated caspase-3 resulting in cell apoptosis (26). Recently, it has been reported that CEP55 silencing promoted breast cancer cell apoptosis (10). Consistent with this report, we found that silencing of CEP55 resulted in a significant increase in apoptotic cells in the NSCLC cells. Moreover, the mechanisms involved activation of anti-apoptotic factors, such as Bcl-2, Bad and caspase-3, as well as subsequent amplification of PARP cleavage.

In conclusion, our in vitro data provided enough evidence that the CEP55 level was elevated in lung cancer and its inhibition significantly suppressed lung cell survival and proliferation. These findings suggested that CEP55 may be a potential therapeutic target in lung cancer treatment.

References